• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cardiovascular therapeutics >Evaluation of the effects of urotensin ii and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients
【24h】

Evaluation of the effects of urotensin ii and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients

机译：评价尿紧张素ii和可溶性环氧化物水解酶抑制剂对健康对照组和心力衰竭患者皮肤微血管张力的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Urotensin II (UII) is a potent vasoactive peptide that exerts differential effects on heart failure (HF) patients compared to health controls. However, the mechanism of action remains unclear. The role of soluble epoxide hydrolase (sEH) as a mediator of UII in the vasculature has not been explored. Aims: The aim of this study was to examine the effect of UII in the presence and absence of sEH inhibitor AUDA on skin microvessel tone in HF patients and healthy controls using iontophoresis and laser Doppler velocimetry. UII (10 -7M) and AUDA (10 -10, 10 -7, and 10 -5M) were administered to the forearm of participants by iontophoresis for 30 seconds. Laser Doppler velocimetry was performed for 5 minutes to measure flux through the subcutaneous blood vessels. Response (flux) was measured for 5 minutes per concentration with 25 continuous scans. Results: UII increased flux in healthy controls by 39% (P 0.05) and increased flux in HF patients by 6% (ns). AUDA (10 -10 and 10 -7M) administration further decreased flux by 115% (P 0.05) and 255% (P 0.0001), respectively in healthy controls. In HF patients, AUDA (10 -10, 10 -7, and 10 -5M) further increased flux by 77% (P 0.05), 67% (P 0.01), and 100% (P 0.05), respectively. AUDA alone at 10 -7M increased flux in both groups by 31% (healthy controls, P 0.05) and 36% (HF, P 0.01). Conclusion: Taken together, the presence of HF appeared to abrogate the vasodilator responsiveness of sEH inhibitor. These results suggest an important role for both UII and sEH in vascular regulation and that sEH may be involved in mediating UII effects. Furthermore, the study highlights the therapeutic potential of sEH inhibitors for the treatment of HF.
机译：简介：降压肽II（UII）是一种有效的血管活性肽，与健康对照相比，它对心力衰竭（HF）患者产生不同的作用。但是，作用机理仍不清楚。尚未探讨可溶性环氧化物水解酶（sEH）作为UII在脉管系统中的介体的作用。目的：本研究的目的是使用离子电渗疗法和激光多普勒测速仪检查存在和不存在sEH抑制剂AUDA的UII对HF患者和健康对照者皮肤微血管张力的影响。通过离子电渗疗法将UII（10 -7M）和AUDA（10 -10、10 -7和10 -5M）施用到参与者的前臂，持续30秒。激光多普勒测速仪进行了5分钟，以测量通过皮下血管的流量。在25次连续扫描中，每个浓度测定了5分钟的响应（通量）。结果：UII使健康对照组的通量增加39％（P <0.05），而HF患者的通量增加6％（ns）。在健康对照组中，使用AUDA（10 -10和10 -7M）分别使通量分别降低了115％（P <0.05）和255％（P <0.0001）。在HF患者中，AUDA（10 -10、10 -7和10 -5M）分别使通量分别增加了77％（P <0.05），67％（P <0.01）和100％（P <0.05）。单独的AUDA在10 -7M时两组的通量分别增加31％（健康对照组，P <0.05）和36％（HF，P <0.01）。结论：总而言之，HF的存在似乎消除了sEH抑制剂的血管舒张反应。这些结果表明，UII和sEH在血管调节中均起着重要作用，而sEH可能参与介导UII的作用。此外，该研究还强调了sEH抑制剂在治疗HF中的治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号